Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

Expert opinion on emerging drugs - 1 Sept 2020

Fujino Toshio, Suda Kenichi, Mitsudomi Tetsuya

Abstract excerpt

Introduction MET aberrations, including MET exon 14 skipping mutation and amplification, are present in ~5% of non-small cell lung cancer (NSCLC) cases, and these levels are comparable to the frequency of ALK fusion. MET amplification also occurs as an acquired resistance mechanism in EGFR-mutated NSCLC after EGFR tyrosine kinase inhibitors (TKI) treatment failure. Therefore, the development of therapies for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Development
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 32615820
DOI: 10.1080/14728214.2020.1791821

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.PMID 32615820Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET alterations in NSCLC-Current Perspectives and Future Challenges.Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.Semantic proximity Read ↗

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping MutationSemantic proximity Read ↗

Meeting an un-MET need: Targeting MET in non-small cell lung cancerSemantic proximity Read ↗

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.Semantic proximity Read ↗

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.